干扰素α2b联合阿昔洛韦对病毒性肺炎患儿免疫功能的影响

Effect of interferon α2b combined with acyclovir on immune function in children with viral pneumonia

  • 摘要:
      目的  探讨干扰素α2b联合阿昔洛韦对病毒性肺炎患儿免疫功能的影响。
      方法  选取病毒性肺炎患儿150例,随机分为空白对照组、对照组和观察组,每组50例。空白对照组不接受任何抗病毒药物治疗,对照组在常规治疗基础上给予阿昔洛韦,观察组在对照组的基础上给予重组人干扰素α2b注射液。比较患儿临床症状改善情况; 测定T淋巴细胞亚群、炎性因子淀粉样蛋白A(SAA)、超敏C反应蛋白(hs-CRP)水平,分析临床疗效。
      结果  治疗后,观察组患儿临床症状改善时间短于空白对照组、对照组,差异有统计学意义(P < 0.05); 治疗后,患儿血清CD4+、CD4+/CD8+、SAA、hs-CRP水平低于治疗前, CD3+、CD8+水平高于治疗前,差异有统计学意义(P < 0.05); 治疗后,观察组血清CD4+、CD4+/CD8+、SAA、hs-CRP水平低于空白对照组、对照组, CD3+、CD8+水平高于空白对照组、对照组,差异有统计学意义(P < 0.05)。观察组的治疗总有效率高于空白对照组、对照组,差异有统计学意义(P < 0.05)。
      结论  干扰素α2b联合阿昔洛韦治疗病毒性肺炎患儿疗效确切,可有效改善临床症状,提高患儿机体免疫力,抑制机体炎性反应,有助于疾病转归。

     

    Abstract:
      Objective  To explore the effect of interferon α2b combined with acyclovir on immune function in children with viral pneumonia.
      Methods  A total of 150 children with viral pneumonia were randomly divided into blank control group, control group and observation group, with 50 cases in each group. The blank control group did not receive any antiviral drugs, the control group was given acyclovir in addition to conventional treatment, and the observation group was given recombinant human interferon α2b injection on the basis of the control group. The improvement of clinical symptoms was compared. The levels of T lymphocyte subsets, inflammatory factors amyloid A (SAA) and high-sensitivity C-reactive protein (hs-CRP)were measured, and the clinical efficacy was analyzed.
      Results  After treatment, the improvement time of clinical symptoms in the observation group was significantly shorter than that in the blank control group and control group (P < 0.05); after treatment, the serum levels of CD4+, CD4+/CD8+, SAA and hs-CRP were significantly lower, while the levels of CD3+ and CD8+ were significantly higher than before treatment (P < 0.05); the serum levels of CD4+, CD4+/CD8+, SAA and hs-CRP in the observation group were significantly lower, while the levels of CD3+ and CD8+ were significantly higher than those in the blank control group and control group (P < 0.05). The total effective rate of the observation group was significantly higher than that of the blank control group and control group (P < 0.05).
      Conclusion  Interferon α2b combined with acyclovir is effective in the treatment of children with viral pneumonia, which can effectively improve the clinical symptoms, enhance the immune capacity of children, inhibit the inflammatory response, and is conductive to the outcome of the disease.

     

/

返回文章
返回